umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Immune responses to neoadjuvant chemotherapy in muscle invasive bladder cancer
Umeå University, Faculty of Medicine, Department of Surgical and Perioperative Sciences, Urology and Andrology.
2018 (English)In: Bladder cancer, ISSN 2352-3727, Vol. 4, no 1, p. 1-7Article in journal (Refereed) Published
Abstract [en]

The secondary effects of chemotherapy, with bone marrow depression and risk of leukopenia, has traditionally been considered being detrimental for the immune system. However, growing evidence suggests a main role for chemotherapy in antitumor immunomodulation. With reference to cisplatin, which is the basis of neoadjuvant chemotherapy in muscle invasive bladder cancer, four different aspects of immunomodulation has thus far been described; increased MHC class I expression, recruitment and proliferation of effector cells, enhancement of tumor-lytic activity of cytotoxic effectors and downregulation of immunosuppressive actors in the microenvironment. Consequently, the role of chemotherapy in cancer is changing from a therapy solely aimed at inducing tumor cell death, to a potent inducer of immune responses and a potential future major partaker in cancer immunotherapy. This is a great opportunity for the urological community to broaden research in this field in order to increase knowledge, optimize and improve the neoadjuvant regimens of muscle invasive bladder cancer to ultimately improve patient outcome.

Place, publisher, year, edition, pages
IOS Press, 2018. Vol. 4, no 1, p. 1-7
Keywords [en]
B-lymphocytes, T-lymphocytes, Urinary bladder neoplasms, antigen-presenting cells, cisplatin, neoadjuvant therapy
National Category
Urology and Nephrology
Identifiers
URN: urn:nbn:se:umu:diva-146189DOI: 10.3233/BLC-170123ISI: 000431147500001PubMedID: 29430502OAI: oai:DiVA.org:umu-146189DiVA, id: diva2:1194467
Available from: 2018-04-03 Created: 2018-04-03 Last updated: 2018-06-09Bibliographically approved

Open Access in DiVA

fulltext(196 kB)49 downloads
File information
File name FULLTEXT01.pdfFile size 196 kBChecksum SHA-512
7cdf2df48a8235fce353ea5c1b1e512a712ac14e5f7b67073f07ed36bef69e7538057ae8bbf44247ec4306c3a68151e138e6ee95fcffb67dde64bb9ca06d57a6
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records BETA

Sherif, Amir

Search in DiVA

By author/editor
Sherif, Amir
By organisation
Urology and Andrology
Urology and Nephrology

Search outside of DiVA

GoogleGoogle Scholar
Total: 49 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 197 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf